Healthcare Industry News: Lauriad
News Release - June 26, 2006
BioAlliance Pharma Strengthens Operational Management Ahead of Loramyc(R) LaunchPARIS--(HSMN NewsFeed)--June 26, 2006--BioAlliance Pharma SA (Paris:BIO ), an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections, announced today it has filled three new operational management positions in preparation for the launch of its lead product, Loramyc®. The three new arrivals all have extensive industry experience. They are: Fabrice Auzelle, Lauriad® Medical Project Manager, David Weinstein, European Scientific Affairs Manager and Sylvia Galli, Sales Manager, Laboratoires BioAlliance Pharma, BioAlliance Pharma's sales and marketing subsidiary. The Marketing Authorization Approval (MAA) for Loramyc® is under review by the French Agency (AFSAPPS) and is expected in Q4 2006.
"These new managers bring substantial operational experience to BioAlliance Pharma ahead of the launch of Loramyc in France and Europe, where we have a Marketing Authorization pending," said Dominique Costantini, MD, president and CEO of BioAlliance Pharma. "A pivotal phase III study is currently under way in the US."
Mr. Auzelle, 38, joins the Lauriad® business unit and will have special responsibility for Loramyc® clinical trials in the US as well as other clinical applications of Lauriad® technology. Mr. Auzelle was head of the regulatory and project department at Quintiles and later at IDM. He began his career in the French Army medical research center. He has a DEA post-graduate diploma in neurosciences and clinical and fundamental neuro-immuno-pharmacology from the University of Lyon I.
Mr. Weinstein, 40, has American and French nationality, and will be part of the sales and marketing department. His previous position was as medical director, medical affairs, anti-infectives, Europe at Gilead Sciences EHQ. Earlier he was in charge of international outcomes research at Pfizer Global Pharmaceuticals, France, and has worked in international development at Wyeth. Mr. Weinstein has an MS in Health Policy from the London School of Economics coupled with the London School of Hygiene and Tropical medicine.
Ms Galli, 45, will be based in BioAlliance Pharma's sales and marketing subsidiary, Laboratoires BioAlliance Pharma. Her previous post was as sales manager at Sanofi-Aventis's dermatology and HIV virology unit. She has accumulated considerable experience in marketing and sales in the field of oncology having worked for Sandoz, Eurocetus, Amgen, Bellon, Rhone-Poulenc-Rorer and Aventis. She has a diploma from the experimental oncology department of the faculty of medicine in Marseilles.
About BioAlliance Pharma
BioAlliance Pharma SA (Euronext Paris: BIO) is an emerging specialty pharmaceutical company focused on the development of innovative therapeutics targeting drug resistance in cancer, HIV, and severe and opportunistic infections. The Company is developing three broad product ranges based on the Lauriad® adhesive technology which allows an early and prolonged release of therapeutic agents at the site of the disease, the Transdrug® nanoparticle technology designed specifically for intracellular targeting, and a New Chemical Entities program focused on development of new drugs in oncology and HIV.
The Company's most advanced product, the Loramyc® (miconazole Lauriad®) 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in Europe for treatment of oropharyngeal candidiasis (OPC) in cancer and HIV patients. In September 2005, BioAlliance filed a request for Marketing Authorisation (MAA) in Europe for this product. Under an IND allowed by the US Food and Drug Administration (FDA), a pivotal Phase III trial of Loramyc® is ongoing in the US in 2006 for the same indication. A second product, acyclovir Lauriad®, for the treatment of oral herpes, has completed a Phase I clinical trial in Europe. A Phase I/II trial in primary liver cancer (hepatocellular carcinoma or HCC) utilizing the Company's doxorubicin Transdrug® nanoparticle delivery technology is ongoing in Europe, and has been granted orphan drug status by the EMEA and the FDA.
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements please refer to the Risk Factors (Facteurs de Risque) section of the reference document approved by the AMF on 28 April 2006 under the number R. 06-042, which is available on the AMF website http://www.amf-france.org or BioAlliance Pharma S.A.'s website http://www.bioalliancepharma.com.
Source: BioAlliance Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.